JPRN-UMIN000014531已完成未知
The effects of anaglipitin, a DPP-4 inhibitor, on blood lipids in type 2 diabetic patients. - Anagliptin effects on lipids (ANGELS)
Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine0 个研究点目标入组 24 人开始时间: 2014年7月11日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
Treatment with anagliptin for 24 weeks significantly reduced fasting serum apolipoprotein (Apo) B-48 compared with the control group (P < 0.05).
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Type 1 diabetes Treatment with insulin, glinides, high doses of SU Patients with repetitive or unaware severe hypoglycemia Severe liver diseases Patients with hemodialysis Severe cardiac diseases or acute myocardial infarction within 6 months Severe anemia Severe pancreatitis Malignant diseases Uncontrolled endocrine diseases Severe infections or surgical treatment Severe diabetic complications Severe bowel diseases Alcohol addiction Pregnant or possibly pregnant women History of allergic reaction to DPP4 inhibitors Patients who a physician-in-charge considers is unsuitable for the trial.
研究者
相似试验
已完成
不适用
ANGELSType 2 Diabetes MellitusJPRN-jRCTs041180085Arima Hiroshi24
已完成
4 期
Effect of alogliptin , a DPP-4 inhibitor, on markers of lipid metabolism in type 2 diabetic patientsJPRN-UMIN000011470ara Hospital Kinki University Faculty of Medicine50
已完成
不适用
The impact of DPP-4 inhibitor on daily glucose profile and coronary plaque character in impaired glucose tolerance patients with coronary artery diseasepatients with coronary artery disease and impaired glucose tolerance (IGT)JPRN-UMIN000008620Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine24
已完成
不适用
The lipid lowering effect of anagliptin in type2 diabetes mellitus with dyslipidemiaType2 diabetes mellitus patients with dyslipidemiaJPRN-UMIN000013682Internal Medicine, Teikyo University School of Medicine40
已完成
不适用
PROUD48JPRN-jRCTs071200011Takeda Yasutaka129